Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 17/20 | 0.58 |
| ▸ | LPL | P06858 | 6/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.56 |
| ▸ | LIPC | P11150 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210096 | 0.91 | LIPG (0.61) | LIPGLPLFFAR4LIPC | |
| SCHEMBL1410556 | 0.90 | LIPG (0.60) | LIPGLPLFFAR4LIPC | |
| SCHEMBL12210090 | 0.89 | LIPG (0.58) | LIPGLPLFFAR4LIPCFFAR1 | |
| SCHEMBL1410173 | 0.88 | LIPG (0.57) | LIPGLPLFFAR4LIPCFFAR1 | |
| SCHEMBL12210088 | 0.86 | LIPG (0.61) | LIPGLPLFFAR4LIPC | |
| SCHEMBL12210053 | 0.85 | NOTUM (0.49) | LIPGLPLLIPC | |
| SCHEMBL1409553 | 0.84 | NOTUM (0.48) | LIPGLPLLIPC | |
| SCHEMBL1410148 | 0.82 | NOTUM (0.60) | LIPGLPLFFAR4LIPC | |
| SCHEMBL1410302 | 0.82 | LIPG (0.55) | LIPGLPLLIPC | |
| SCHEMBL2517781 | 0.81 | LIPG (0.49) | LIPGLPLLIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009145286-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | LIPG 3938/4885LPL 3718/4885FFAR4 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.